Lakefront Biotherapeutics (LKFT) Total Non-Current Liabilities (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Total Non-Current Liabilities for 13 consecutive years, with $21.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 97.52% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $21.8 million (down 97.52% YoY), while the FY2025 annual figure was $20.7 million, down 97.86% from the prior year.
• Total Non-Current Liabilities improved to $21.8 million in Q1 2026 per LKFT's latest filing, from $20.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $2.1 billion in Q1 2022 and bottomed at $20.7 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities retreated 20.83% — and 2025, when it sank 97.86%.
• Lakefront Biotherapeutics' Total Non-Current Liabilities stood at $1.7 billion in 2022, then decreased by 29.08% to $1.2 billion in 2023, then slipped by 20.83% to $965.7 million in 2024, then tumbled by 97.86% to $20.7 million in 2025, then grew by 5.38% to $21.8 million in 2026.
• Business Quant data shows LKFT's Total Non-Current Liabilities at $21.8 million in Q1 2026, $20.7 million in Q4 2025, and $816.5 million in Q3 2025.